Follow
Xbrane Biopharma AB
Nasdaq First North Sweden (Sweden)
Xbrane Biopharma AB is a biopharmaceutical company, develops and manufactures biosimilars and generic long-acting injectables. It offers products including Spherotide, a long-acting injectable with the active substance triptorelin for the treatment of prostate cancer, breast cancer, endometriosis, and myoma and Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes-related macular edema, diabetic retinopathy, and retinal vein occlusion. The company has two segments Xbrane Biopharma AB is a biopharmaceutical company, develops and manufactures biosimilars and generic long-acting injectables. It offers products including Spherotide, a long-acting injectable with the active substance triptorelin for the treatment of prostate cancer, breast cancer, endometriosis, and myoma and Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes-related macular edema, diabetic retinopathy, and retinal vein occlusion. The company has two segments that are Biosimilars and Long-acting Injectables.

Read more

Sector:
HEALTH CARE
>
Drug Manufacturers - Specialty & Generic
Media
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
XBRANE
SE0007789409
Nasdaq First North Sweden
Sweden (SE)
Details of share in Xbrane Biopharma AB with ticker XBRANE
Status
Active
Order book id
Amount of instruments
8 307 126
Par value
0.2242
Market cap
Currency
SEK
Segment
First North
First trading date
03 Feb 2016
Terms
Type
Price
Pre-money valuation
Time
IPO
42.50 SEK
95M SEK
07 Jan - 21 Jan 2016
IPO in Xbrane Biopharma AB
Market
Nasdaq First North Sweden
Subscription period
07 Jan - 21 Jan 2016
Subscription price
Price per share
42.50 SEK
Target to raise
100 300 000 SEK
Types
Pre-money valuation
95 000 000 SEK
Subscription block size
Minimum subscription
250
Record date
Offer status
Closed
Listing status
Listed
First trading date
03 Feb 2016
Issue terms
Turns to the public, without preferential rights for existing shareholders.
Type
Price
Pre-money valuation
Time
New issue
30.00 SEK
189.9M SEK
11 Mar - 25 Mar 2019
Share issue in Xbrane Biopharma AB
Market
Nasdaq First North Sweden
Subscription period
11 Mar - 25 Mar 2019
Subscription price
30.00 SEK
Price per share
30.00 SEK
Target to raise
59 340 000 SEK
Types
Share issue
Pre-money valuation
189 900 000 SEK
Subscription block size
Minimum subscription
Record date
07 Mar 2019
Offer status
Closed
Listing status
Listed
Issue terms
Preference right 5:16. Existing shareholders receive five subscription rights for each share held on the record date. Sixteen (16) subscription rights entitle to subscribe for one (1) new share.
Type
Price
Pre-money valuation
Time
New issue
33.50 SEK
18 Jun 2019
Share issue in Xbrane Biopharma AB
Market
Nasdaq First North Sweden
Subscription date
18 Jun 2019
Subscription price
33.50 SEK
Price per share
33.50 SEK
Target to raise
146 989 458 SEK
Types
Share issue
Pre-money valuation
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
Directed share issue. The subscribers in the Directed Share Issue are, amongst other, STADA Arzneimittel AG, NYIP (Nyenburgh Investment Partners), Swedbank Robur Medica, Belsize Asset Management GmbH and Serendipity Group AB.
Type
Price
Pre-money valuation
Time
New issue
33.50 SEK
238M SEK
28 Jun - 12 Jul 2019
Share issue in Xbrane Biopharma AB
Market
Nasdaq First North Sweden
Subscription period
28 Jun - 12 Jul 2019
Subscription price
33.50 SEK
Price per share
33.50 SEK
Target to raise
91 130 988 SEK
Types
Share issue
Pre-money valuation
238 000 000 SEK
Subscription block size
Minimum subscription
Record date
26 Jun 2019
Offer status
Closed
Listing status
Listed
Issue terms
Preferential subscription 3:14. One existing share gives right to one subscription right and 14 subscription rights entitles the holder to subscribe for 3 new shares.
Result of offer
The final outcome for Xbrane Biopharma 94 percent guaranteed rights issue shows that 1,808,682 shares, corresponding to approximately 66.5 percent of the shares offered, were subscribed for by exercise of subscription rights. Additionally, 394,177 shares corresponding to approximately 14.5 percent of the Right Issue was subscribed without use of subscription rights. The remaining part of the Rights Issue, corresponding to 517,469 shares or approximately 19 percent was subscribed by the guarantors. The Company receives approximately SEK 91 million before deduction for issue costs from the Rights Issue.
People
Number of Employees
35 people
Karl Martin Erik Åmark
CEO
Anders Tullgren
Chairman of the board
Anders Tullgren
Board member
Prof. Saeid Esmaeilzadeh
Board member
Prof. Maris Hartmanis
Board member
Karin Wingstrand
Board member
Prof.Peter Edman
Board member
Giorgi Chirivi
Board member
Alessandro Sidoli
Board member
Company Details
Sector
HEALTH CARE
Website

Address
Banvaktsvägen 22
Zip code
171 48
City/district
Solna
Country
Sweden (SE)
Registration number
556749-2375
LEI code
5493008DKD05APTKQO39
First trade date
03 Feb 2016
Registration date
15 Jan 2008
Short name
Xbrane Biopharma